New Drug Applications Approval for Five New Products in Japan
Takeda Pharmaceutical Company Limited announced that New Drug Applications for five new products were approved on April 16 by the Japanese Ministry of Health, Labour and Welfare.
Five new products approved for commercial sale in Japan comprise three new medical entities; “NESINA®” for treatment of type 2 diabetes, “ROZEREM®” for treatment of insomnia and anti-cancer agent “Vectibix®”, and two fixed dose combinations; “METACT®” for treatment of type 2 diabetes and “UNISIA®” for treatment of hypertension, each of them contains two compounds with a different mechanism of action respectively.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.